Eli Lilly at 41 Times Earnings: What the Tirzepatide Franchise Has to Deliver
Eli Lilly closed at USD 1,220.28 on the US market on 12 August 2026. Applied to trailing twelve-month earnings per share, that gives a price-to-earnings ratio of about 41.0.
A ratio of 41 is neither expensive nor cheap on its own. What it means depends on the growth it assumes.
This article takes that assumption apart: where the revenue comes from, what raises it and what erodes it, and which conditions would have to fail for the assumption to break down.
Table of Contents
- What Eli Lilly's Valuation Assumes
- The Structure and Requirements of the Tirzepatide Business
- What the Revenue Data Shows
- The Conditions That Keep the Growth Premium in Place
- How Eli Lilly Differs From Novo Nordisk
- Limits of the Investment Case
- Frequently Asked Questions
- Summary
1. What Eli Lilly's Valuation Assumes
The price-to-earnings ratio divides the share price by earnings per share. The closing price of USD 1,220.28 on 12 August 2026 and trailing twelve-month earnings per share of USD 29.79 give a ratio of about 41.0.
The forward price-to-earnings ratio at the same date is about 29.7. The gap between the two figures indicates that the market expects earnings over the coming twelve months to rise considerably.
That expectation is not unfounded. Trailing twelve-month revenue was USD 79.67 billion, up 49.6%, and net income over the same period was USD 26.71 billion, up 93.6%. On 5 August the company raised its 2026 full-year revenue guidance from USD 82–85 billion to USD 85–87 billion.
The question is how long that pace continues. Answering it requires looking at how the revenue is produced.
2. The Structure and Requirements of the Tirzepatide Business
At the centre of Eli Lilly's growth is a single active substance, tirzepatide. It is sold under different brands depending on the indication.
| Brand | Principal US FDA indication | Approval date | Condition |
|---|---|---|---|
| Mounjaro | Type 2 diabetes | 13 May 2022 | For improving glycaemic control |
| Zepbound | Chronic weight management in obesity or overweight | 8 November 2023 | Includes a weight-related comorbidity requirement |
| Zepbound, added indication | Moderate-to-severe obstructive sleep apnoea | 20 December 2024 | For adults with obesity |
Data as of 12 August 2026. One substance, two brands. Under the US FDA label, Mounjaro is not an obesity medicine but a type 2 diabetes medicine. The brand carrying the obesity indication is Zepbound.
The addition of obstructive sleep apnoea in December 2024 widened the substance's reach from weight loss to obesity-related disease. As indications accumulate, treatment periods lengthen and revenue becomes recurring.
3. What the Revenue Data Shows
Revenue in the second quarter of 2026 was USD 23.0 billion, an increase of 48% year on year.
Source: Eli Lilly second-quarter 2026 results, 5 August 2026
The four items in the chart overlap. Mounjaro revenue was USD 9.9 billion worldwide and Zepbound revenue was USD 4.9 billion in the United States, while the company reported combined revenue for the two brands of USD 14.9 billion. That is about 65% of total revenue for the quarter.
By region, US Mounjaro revenue was USD 4.8 billion, up 45%, while revenue outside the United States was USD 5.2 billion, up 172%. The centre of gravity for growth is shifting away from the US market.
4. The Conditions That Keep the Growth Premium in Place
In the same quarter, volume grew 60% while realised prices fell 13%. These two figures explain the structure behind the revenue growth rate.
Revenue growth emerges roughly as volume growth offset by the decline in realised prices. At present volume is rising much faster, which is how the figure of 48% was produced.
For the growth premium to hold, three pillars therefore have to bear weight together. The first is volume growing faster than prices fall; the second is the oral formulation bringing new patients into the market; the third is the pipeline converting into actual approvals.
If any one of the three pillars gives way, the basis for a multiple of 41 weakens.
5. How Eli Lilly Differs From Novo Nordisk
The two companies operate in the same market, but the market values them differently.
| Comparison | Eli Lilly | Novo Nordisk |
|---|---|---|
| Active substance | Tirzepatide | Semaglutide |
| Mechanism | Dual GIP and GLP-1 receptor agonist | GLP-1 receptor agonist |
| Obesity brand | Zepbound | Wegovy |
| Oral GLP-1 | Foundayo, US approval 1 April 2026 | Wegovy pill, US launch 5 January 2026 |
| Closing price, 12 August 2026 | USD 1,220.28 | USD 46.39 |
| Price-to-earnings ratio | About 41.0 | About 11.6 |
| Forward price-to-earnings ratio | About 29.7 | About 15.6 |
Data as of the 12 August 2026 US market close. The price-to-earnings ratio is the closing price divided by trailing twelve-month earnings per share.
The line to note is the forward ratio. Eli Lilly moves from 41.0 down to 29.7, while Novo Nordisk moves from 11.6 up to 15.6. The market has already priced in earnings rising at one company and falling at the other.
There is also evidence on efficacy. In SURMOUNT-5, which tested the two substances head to head, mean weight loss at 72 weeks was 20.2% with tirzepatide and 13.7% with semaglutide. The trial enrolled 751 participants across 32 sites in the United States and Puerto Rico, and the results were published in the New England Journal of Medicine.
The comparator in that trial, however, was semaglutide at a maximum of 2.4 mg. The higher-dose Wegovy HD 7.2 mg, approved in March 2026, was not included.
6. Limits of the Investment Case
The first limit is concentration. About 65% of quarterly revenue comes from two tirzepatide brands. If regulatory or pricing problems affect that class, there is little else to absorb the impact.
The second limit is pipeline uncertainty. In the phase 3 TRIUMPH-1 trial, participants receiving retatrutide 12 mg recorded mean weight loss of 28.3% at 80 weeks, and more than 45% of participants lost 30% or more. Among participants with a baseline body mass index of 35 or above who entered a study extension, mean weight loss reached 30.3% at 104 weeks. The company released these results on 21 May 2026.
The figures are strong, but the stage is different. As of August 2026 retatrutide is not an approved medicine and is not available outside clinical trials. Reuters reported on 12 August 2026 that Eli Lilly had sued six companies over alleged illegal sales of the candidate.
The third limit is the valuation itself. A multiple of 41.0 rests on the premise that growth continues. Even if earnings rise, the share price can fall if they rise more slowly than the market expects. Corporate strength and investment return are not the same measure.
7. Frequently Asked Questions
Q. How do Mounjaro and Zepbound differ?
A. The active substance, tirzepatide, is the same. Under the US FDA label, the principal indication for Mounjaro is type 2 diabetes, while Zepbound covers chronic weight management in obesity or overweight and moderate-to-severe obstructive sleep apnoea in adults with obesity.
Q. Can retatrutide be prescribed now?
A. No. As of August 2026 it is not an approved medicine and is not available outside clinical trials.
Q. Is a price-to-earnings ratio of 41 expensive?
A. It is not a figure that can be judged on its own. A forward ratio of about 29.7 at the same date indicates that the market assumes earnings will rise, and whether that assumption holds will only be confirmed by later results.
8. Summary
Eli Lilly's growth has been built by expanding indications and brands from a single active substance, tirzepatide. In the second quarter of 2026 that structure produced revenue of USD 23.0 billion and growth of 48%.
The same structure is also the risk. About 65% of revenue comes from one class, volume growth is running against falling prices, and the next growth axis, retatrutide, remains a pre-approval candidate.
Whether a multiple of 41 holds depends on volume growth, new patient inflow and pipeline approval being confirmed together in the next set of results.
Investment Disclaimer
This article is provided for information and analysis based on publicly available materials, and does not recommend the purchase, sale or holding of any financial product or real estate asset.
The figures and outlooks cited here reflect the sources available at the time of writing and may change thereafter. Regulations, tax rates, interest rates and eligibility rules apply differently depending on the effective date and on individual circumstances.
All investment decisions and any resulting gains or losses are the sole responsibility of the investor. Please consult a qualified financial, tax or real estate professional before acting on this information.
댓글
댓글 쓰기